Amgen Statistics
Total Valuation
Amgen has a market cap or net worth of $251.89 billion. The enterprise value is $292.70 billion.
| Market Cap | 251.89B |
| Enterprise Value | 292.70B |
Important Dates
The last earnings date was Tuesday, November 3, 2026, after market close.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | Nov 20, 2026 |
Share Statistics
Amgen has 540.91 million shares outstanding. The number of shares has increased by 0.46% in one year.
| Current Share Class | 540.91M |
| Shares Outstanding | 540.91M |
| Shares Change (YoY) | +0.46% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 83.83% |
| Float | 539.44M |
Valuation Ratios
The trailing PE ratio is 26.98 and the forward PE ratio is 19.20. Amgen's PEG ratio is 3.51.
| PE Ratio | 26.98 |
| Forward PE | 19.20 |
| PS Ratio | 6.47 |
| Forward PS | 6.12 |
| PB Ratio | 17.55 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 26.29 |
| P/OCF Ratio | 20.93 |
| PEG Ratio | 3.51 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.60, with an EV/FCF ratio of 30.55.
| EV / Earnings | 31.17 |
| EV / Sales | 7.52 |
| EV / EBITDA | 16.60 |
| EV / EBIT | 22.05 |
| EV / FCF | 30.55 |
Financial Position
The company has a current ratio of 1.48, with a Debt / Equity ratio of 3.76.
| Current Ratio | 1.48 |
| Quick Ratio | 1.01 |
| Debt / Equity | 3.76 |
| Debt / EBITDA | 3.02 |
| Debt / FCF | 5.64 |
| Interest Coverage | 4.36 |
Financial Efficiency
Return on equity (ROE) is 78.35% and return on invested capital (ROIC) is 20.48%.
| Return on Equity (ROE) | 78.35% |
| Return on Assets (ROA) | 8.91% |
| Return on Invested Capital (ROIC) | 20.48% |
| Return on Capital Employed (ROCE) | 18.23% |
| Weighted Average Cost of Capital (WACC) | 6.23% |
| Revenue Per Employee | $1.24M |
| Profits Per Employee | $298,127 |
| Employee Count | 31,500 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 1.68 |
Taxes
In the past 12 months, Amgen has paid $1.66 billion in taxes.
| Income Tax | 1.66B |
| Effective Tax Rate | 15.03% |
Stock Price Statistics
The stock price has increased by +38.48% in the last 52 weeks. The beta is 0.42, so Amgen's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | +38.48% |
| 50-Day Moving Average | 425.31 |
| 200-Day Moving Average | 381.01 |
| Relative Strength Index (RSI) | 61.77 |
| Average Volume (20 Days) | 2,697,759 |
Short Selling Information
The latest short interest is 12.59 million, so 2.33% of the outstanding shares have been sold short.
| Short Interest | 12.59M |
| Short Previous Month | 13.38M |
| Short % of Shares Out | 2.33% |
| Short % of Float | 2.33% |
| Short Ratio (days to cover) | 4.71 |
Income Statement
In the last 12 months, Amgen had revenue of $38.90 billion and earned $9.39 billion in profits. Earnings per share was $17.26.
| Revenue | 38.90B |
| Gross Profit | 28.19B |
| Operating Income | 13.27B |
| Pretax Income | 11.05B |
| Net Income | 9.39B |
| EBITDA | 17.63B |
| EBIT | 13.27B |
| Earnings Per Share (EPS) | $17.26 |
Balance Sheet
The company has $13.19 billion in cash and $54.01 billion in debt, with a net cash position of -$40.82 billion or -$75.46 per share.
| Cash & Cash Equivalents | 13.19B |
| Total Debt | 54.01B |
| Net Cash | -40.82B |
| Net Cash Per Share | -$75.46 |
| Equity (Book Value) | 14.35B |
| Book Value Per Share | 26.53 |
| Working Capital | 11.13B |
Cash Flow
In the last 12 months, operating cash flow was $12.04 billion and capital expenditures -$2.45 billion, giving a free cash flow of $9.58 billion.
| Operating Cash Flow | 12.04B |
| Capital Expenditures | -2.45B |
| Depreciation & Amortization | 4.36B |
| Net Borrowing | -152.00M |
| Free Cash Flow | 9.58B |
| FCF Per Share | $17.71 |
Margins
Gross margin is 72.46%, with operating and profit margins of 34.12% and 24.14%.
| Gross Margin | 72.46% |
| Operating Margin | 34.12% |
| Pretax Margin | 28.41% |
| Profit Margin | 24.14% |
| EBITDA Margin | 45.32% |
| EBIT Margin | 34.12% |
| FCF Margin | 24.63% |
Dividends & Yields
This stock pays an annual dividend of $10.08, which amounts to a dividend yield of 2.17%.
| Dividend Per Share | $10.08 |
| Dividend Yield | 2.17% |
| Dividend Growth (YoY) | 5.88% |
| Years of Dividend Growth | 15 |
| Payout Ratio | 58.40% |
| FCF Payout Ratio | 56.91% |
| Buyback Yield | -0.46% |
| Shareholder Yield | 1.70% |
| Earnings Yield | 3.71% |
| FCF Yield | 3.80% |
Analyst Forecast
The average price target for Amgen is $431.81, which is -7.27% lower than the current price. The consensus rating is "Hold".
| Price Target | $431.81 |
| Price Target Difference | -7.27% |
| Analyst Consensus | Hold |
| Analyst Count | 34 |
| Revenue Growth Forecast (3Y) | 5.56% |
| EPS Growth Forecast (3Y) | 6.96% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on November 22, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Nov 22, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Amgen has an Altman Z-Score of 2.11 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.11 |
| Piotroski F-Score | 8 |